{"DataElement":{"publicId":"2005628","version":"4","preferredName":"Common Toxicity Criteria Adverse Event Hyperuricemia Grade","preferredDefinition":"in CTC category Metabolic/Laboratory, assessment of the severity of a serum-high uric acid (hyperuricemia) adverse event using a graded scale.","longName":"CTC_AE_HYPERURIC_GD","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2193357","version":"1","preferredName":"Common Toxicity Criteria Adverse Event Hyperuricemia","preferredDefinition":"information related to the CTC adverse event of hyperuricemia.","longName":"CTC_AE_HYPERURICEMIA","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2480706","version":"1","preferredName":"Common Terminology Criteria for Adverse Events","preferredDefinition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","longName":"C49704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Common Terminology Criteria for Adverse Events","conceptCode":"C49704","definition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"133A63CA-49B0-49FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-07","modifiedBy":"ONEDATA","dateModified":"2006-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2193355","version":"1","preferredName":"Hyperuricemia","preferredDefinition":"Elevated blood concentrations of uric acid.","longName":"Hyperuricemia","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Hyperuricemia","conceptCode":"C3961","definition":"Elevated blood concentrations of uric acid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EAC0FC16-205F-2297-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-12-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-12-10","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EAC0FC16-2065-2297-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-12-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-12-10","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2017827","version":"3","preferredName":"Common Toxicity Criteria Adverse Event Hyperuricemia Grade","preferredDefinition":"in CTC category Metabolic/Laboratory, assessment of the severity of a serum-high uric acid (hyperuricemia) adverse event using a graded scale.","longName":"CTC_AE_HYPERURIC_GD","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"NUMBER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"5","valueDescription":"Death","ValueMeaning":{"publicId":"2561497","version":"1","preferredName":"Death","longName":"2561497","preferredDefinition":"The absence of life or state of being dead.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dead","conceptCode":"C28554","definition":"The cessation of life.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BD46-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-05","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-07-05","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4F01299-966D-6830-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-15","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"3","valueDescription":">ULN - 10 mg/dL; <= 0.59 mmol/L with physiologic consequences","ValueMeaning":{"publicId":"2563328","version":"1","preferredName":">ULN - 10 mg/dL; <= 0.59 mmol/L with physiologic consequences","longName":"2563328","preferredDefinition":">ULN - 10 mg/dL; <= 0.59 mmol/L with physiologic consequences","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C46D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-10-11","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-11","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4F01299-9671-6830-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-15","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"4","valueDescription":">10 mg/dL; >0.59 mmol/L","ValueMeaning":{"publicId":"2563329","version":"1","preferredName":">10 mg/dL; >0.59 mmol/L","longName":"2563329","preferredDefinition":">10 mg/dL; >0.59 mmol/L","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C46E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-10-11","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-11","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4F01299-9673-6830-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-15","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"0","valueDescription":"WITHIN NORMAL LIMITS","ValueMeaning":{"publicId":"2564104","version":"1","preferredName":"WITHIN NORMAL LIMITS","longName":"2564104","preferredDefinition":"a reported laboratory value that is within the institutional range of values for normal","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C775-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-01-21","endDate":null,"createdBy":"PWEST","dateCreated":"2003-01-21","modifiedBy":"PWEST","dateModified":"2003-01-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4F01299-9675-6830-E034-0003BA12F5E7","beginDate":"2003-01-21","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-15","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"1","valueDescription":">ULN - 10 mg/dL; <= 0.59 mmol/L without physiologic consequences","ValueMeaning":{"publicId":"2571471","version":"1","preferredName":">ULN - 10 mg/dL; <= 0.59 mmol/L without physiologic consequences","longName":"2571471","preferredDefinition":">ULN - 10 mg/dL; <= 0.59 mmol/L without physiologic consequences","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E43C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-08-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-08-05","modifiedBy":"SHIDED","dateModified":"2004-08-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E0EB3AC8-2ED5-6885-E034-0003BA12F5E7","beginDate":"2004-08-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-08-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2184299","version":"1","preferredName":"Grade","preferredDefinition":"Describes how closely a cancer resembles normal tissue of its same type, and the cancer's probable rate of growth","longName":"Grade","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Histologic Grade","conceptCode":"C18000","definition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-1C87-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTCAE:Common Terminology Criteria for Adverse Events v3.0","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4F01299-9669-6830-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-08-15","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-15","modifiedBy":"MAESKEB","dateModified":"2009-05-06","changeDescription":"updated to meet criteria for CTCAE version 3.0","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2812032","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]},{"publicId":"2604617","version":"1","longName":"Submission and Reporting","context":"CTEP","ClassificationSchemeItems":[{"publicId":"10000132","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"CTC Adverse Event Uric acid s","type":"Preferred Question Text","description":"CTC Adverse Event Uric acid serum-high (hyperuricemia) Grade","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Hyperuricemia Grade","url":null,"context":"CTEP"},{"name":"Source","type":"DATA_ELEMENT_SOURCE","description":"Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)","url":"http://ctep.cancer.gov/reporting/ctc.html","context":"CTEP"}],"origin":"CTCAE:Common Terminology Criteria for Adverse Events v3.0","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C4EF8186-930F-6E58-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-12-10","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-15","modifiedBy":"REEVESD","dateModified":"2011-04-15","changeDescription":"updated to meet criteria for CTCAE version 3.0","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}